Recently, the National Development and Reform Commission completed the optimization and integration of national engineering research centers and national engineering laboratories, and printed and distributed the list of 191 national engineering research centers included into the new sequence management. The “National Engineering Research Center for Chinese Pharmaceutical Manufacturing Technology and New Drug Development” led by Guangzhou Hanfang Pharmaceutical Co., Ltd. (“National Engineering Research Center”) was successfully included into the new sequence management after many tests.
       This optimization and integration is based on the decision and deployment of the CPC Central Committee and the State Council on the optimization and integration of scientific and technological innovation bases. The National Development and Reform Commission, in accordance with the Administrative Measures of National Engineering Research Centers, the Guidelines for the Evaluation of National Engineering Research Centers and relevant requirements, organized the optimization and integration evaluation of those approved national engineering research centers and the national engineering laboratories in two batches. Under the principle of “one meeting the standard and one passing the evaluation”, those engineering centers that meet the new positioning and new standards were included into the new sequence management, while those that failed to meet the new positioning and new standards were eliminated. A total of 350 engineering centers participated in this optimization and integration, and finally 191 were approved and included into the new sequence management, with a passing rate of only 55%, among which only 5 of 10 national engineering research centers in the field of traditional Chinese medicine passed.
      After being included in the new sequence management, the National Engineering Research Center will consider the national and industrial strategic needs as its starting point, apply itself to the inheritance and innovative development of traditional Chinese medicine, focus on the technical “bottlenecks” in the industry development, and build a national strategic scientific and technological force to improve the efficiency of industrial innovation and promote the deep integration of the innovation chain and industry chain. Based on the construction of the Guangdong-Hong Kong-Macao Greater Bay Area, it will help build an innovation highland of traditional Chinese medicine in the Greater Bay Area, and contribute to the goal of building China into a leading innovative country and a powerful nation of science and technology!